Fifth Lane Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Fifth Lane Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,500	Closed	-$302K	–	11
2026 Q1	$302K	Buy	+7,500	New	+$162K	0.37%	41

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fifth Lane Capital's APLS Position: Q2 2026 in Review

Fifth Lane Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 7,500 shares — an estimated $302K sold.

Fifth Lane Capital first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $302K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Fifth Lane Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Fifth Lane Capital sold 7,500 Apellis Pharmaceuticals shares in Q2 2026, an estimated $302K.
Fifth Lane Capital first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Fifth Lane Capital's Apellis Pharmaceuticals position peaked at $302K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Fifth Lane Capital's 13F filing for Q2 2026, filed 6 Aug 2026.